PIONEER

Deliverable D6.7 Elicitation from the Expert Committee Stakeholder Policy Feedback Forum 1/6
Deliverable D6.7 Elicitation from the Expert Committee Stakeholder Policy Feedback Forum 2/6

WP6 has committed to developing a prostate-cancer-specific framework for evidence requirements to support the efficient and targeted use of current treatment options in addition to the appropriate introduction and adoption of new technologies. Developing consensus amongst regulatory and HTA agencies and payers is an important feature of the work.

I. Defining minimum evidence requirements for HTA in different prostate cancer disease settings
II. Identification of potential uncertainties likely to require additional data
III. Development of a core set of reference models for use in economic evaluations for different stages of prostate cancer
IV. Exploration of approaches for high quality real-world evidence collection (via managed entry agreements, registries or others) to address these
V. Consideration of the appropriateness of an overarching modelling framework to explore individual treatments and treatment sequences as the disease goes through its stages
VI. Optimal use of currently available and future health data
VII. Simulation of coverage with evidence development and risk share schemes
VIII. Translation of PIONEER outcomes to policy change

This deliverable was one of a series of calls to seek the views of clinicians and health technology appraisal (HTA) experts in framing the problem statement. Janssen presented four scenarios and a series of questions for discussion.

PIONEER is funded through the IMI2 Joint Undertaking and is listed under grant agreement No. 777492. This joint undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.